Armoured regulatory t cell
AssigneeKing's College London
InventorsRobert Page, Sophie Papa, Shahram Kordasti, Rita Antunes Dos Reis
Life of this patent
Estimating the term…
Abstract
The present invention relates to a regulatory T-cell (Treg) genetically engineered to express a non-activating site-targeting receptor or ligand and a reduced expression level of FAS. Also provided are polynucleotides, vectors, pharmaceutical compositions, methods of genetically engineering the Treg and methods of treatment or prevention of a disease.
Claims26
A regulatory T-cell (Treg) genetically engineered to express:
- a) a non-activating site-targeting receptor or ligand;
- and
- b) a reduced expression level of FAS.
The Treg according to any one of the preceding claims, wherein the site comprises one or more of bone marrow, tumour microenvironment (TME), central nervous system (CNS), lungs, liver, bowel, bladder, large intestine, small intestine and stomach.
The Treg according to any one of the preceding claims, wherein the site comprises bone marrow.
The Treg according to any one of the preceding claims, wherein the non-activating site-targeting receptor or ligand does not comprise an intracellular domain.
The Treg according to any one of the preceding claims, wherein the non-activating site-targeting receptor comprises a non-activating site-targeting antibody or variant thereof.
The Treg according to any one of the preceding claims, wherein the Treg is genetically engineered to further express:
- c) a chemokine receptor or a functional variant thereof.
An or a plurality of polynucleotide sequence(s) comprising:
- a) a nucleotide sequence which reduces the expression level of FAS;
- and
- b) a nucleotide sequence encoding a non-activating site-targeting receptor or ligand;
- and optionally
- c) a nucleotide sequence encoding a chemokine receptor or a functional variant thereof.
A method of modifying a Treg, the method comprising genetically engineering a Treg to express:
- a) a non-activating site-targeting receptor or ligand;
- and
- b) a reduced expression level of FAS.
Dependencies are inferred from the claim text.